Literature DB >> 23836028

Spicing things up: synthetic cannabinoids.

Max Spaderna1, Peter H Addy, Deepak Cyril D'Souza.   

Abstract

RATIONALE: Recently, products containing synthetic cannabinoids, collectively referred to as Spice, are increasingly being used recreationally.
OBJECTIVES: The availability, acute subjective effects-including self-reports posted on Erowid-laboratory detection, addictive potential, and regulatory challenges of the Spice phenomenon are reviewed.
RESULTS: Spice is sold under the guise of potpourri or incense. Unlike delta-9-tetrahydrocannabinol, the synthetic cannabinoids present in Spice are high-potency, high-efficacy, cannabinoid receptor full agonists. Since standard urine toxicology does not test for the synthetic cannabinoids in Spice, it is often used by those who want to avoid detection of drug use. These compounds have not yet been subjected to rigorous testing in humans. Acute psychoactive effects include changes in mood, anxiety, perception, thinking, memory, and attention. Adverse effects include anxiety, agitation, panic, dysphoria, psychosis, and bizarre behavior. Psychosis outcomes associated with Spice provide additional data linking cannabinoids and psychosis. Adverse events necessitating intervention by Poison Control Centers, law enforcement, emergency responders, and hospitals are increasing. Despite statutes prohibiting the manufacture, distribution, and sale of Spice products, manufacturers are replacing banned compounds with newer synthetic cannabinoids that are not banned.
CONCLUSIONS: There is an urgent need for better research on the effects of synthetic cannabinoids to help clinicians manage adverse events and to better understand cannabinoid pharmacology in humans. The reported psychosis outcomes associated with synthetic cannabinoids contribute to the ongoing debate on the association between cannabinoids and psychosis. Finally, drug detection tests for synthetic cannabinoids need to become clinically available.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836028      PMCID: PMC3799955          DOI: 10.1007/s00213-013-3188-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  111 in total

1.  Myocardial infarction associated with use of the synthetic cannabinoid K2.

Authors:  Arshid Mir; Adebisi Obafemi; Amy Young; Colin Kane
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

2.  Synthetic cannabinoid-induced psychosis: two adolescent cases.

Authors:  Olumide O Oluwabusi; Liudmila Lobach; Umair Akhtar; Branden Youngman; Paul J Ambrosini
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-10       Impact factor: 2.576

3.  Risky recreation: synthetic cannabinoids have dangerous effects.

Authors:  Teena M McGuinness; Donna Newell
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  2012-07-15       Impact factor: 1.098

4.  Synthetic cannabinoids in "spice-like" herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market.

Authors:  Ludger Ernst; Katharina Krüger; Rainer Lindigkeit; Hans-Martin Schiebel; Till Beuerle
Journal:  Forensic Sci Int       Date:  2012-06-28       Impact factor: 2.395

5.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

6.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

7.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Authors:  Paolo Fusar-Poli; Paul Allen; Sagnik Bhattacharyya; José A Crippa; Andrea Mechelli; Stefan Borgwardt; Rocio Martin-Santos; Marc L Seal; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

8.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

9.  Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.

Authors:  L S Melvin; G M Milne; M R Johnson; B Subramaniam; G H Wilken; A C Howlett
Journal:  Mol Pharmacol       Date:  1993-11       Impact factor: 4.436

10.  Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Authors:  Liana Fattore; Walter Fratta
Journal:  Front Behav Neurosci       Date:  2011-09-21       Impact factor: 3.558

View more
  65 in total

1.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

2.  Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

Authors:  Christopher J C Rodgman; Christopher D Verrico; Ray B Worthy; Erica E Lewis
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-14

Review 3.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 4.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

5.  K2 and Spice use among a cohort of college students in southeast region of the USA.

Authors:  Kathleen L Egan; Cynthia K Suerken; Beth A Reboussin; John Spangler; Kimberly G Wagoner; Erin L Sutfin; Beata Debinski; Mark Wolfson
Journal:  Am J Drug Alcohol Abuse       Date:  2015-06-01       Impact factor: 3.829

Review 6.  Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.

Authors:  L-S Camilla d'Angelo; George Savulich; Barbara J Sahakian
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

Review 7.  High times for cannabis: Epigenetic imprint and its legacy on brain and behavior.

Authors:  Henrietta Szutorisz; Yasmin L Hurd
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

Review 8.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 9.  Cannabinoid abuse and addiction: Clinical and preclinical findings.

Authors:  L V Panlilio; S R Goldberg; Z Justinova
Journal:  Clin Pharmacol Ther       Date:  2015-05-02       Impact factor: 6.875

10.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.